Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 0.7% – Should You Sell?

Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) dropped 0.7% on Wednesday . The company traded as low as $1.49 and last traded at $1.52. Approximately 16,699 shares traded hands during trading, a decline of 66% from the average daily volume of 49,389 shares. The stock had previously closed at $1.53.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Cyclerion Therapeutics Trading Down 0.7%

The company’s 50-day simple moving average is $1.78 and its 200-day simple moving average is $2.43. The stock has a market capitalization of $5.97 million, a price-to-earnings ratio of -2.03 and a beta of 0.95.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($0.30) EPS for the quarter. Cyclerion Therapeutics had a negative return on equity of 24.61% and a negative net margin of 77.02%.The business had revenue of $0.88 million for the quarter.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.